Comparing the current results to its competitors, Xenetic Biosciences Inc reported Revenue increase in the 2 quarter 2026 by 11.99 % year on year. The sales growth was above Xenetic Biosciences Inc 's competitors' average revenue growth of 6.35 %, achieved in the same quarter.
Xenetic Biosciences Inc , slower than the average decrease reported by the company's competitors of -43.68 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -43.68 %
Xenetic Biosciences Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industry, which is characterized by rapidly advancing technologies and a focus on proprietary products. It competes with major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research organizations. Competitors may possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. Industry mergers and acquisitions may lead to increased resource concentration among fewer competitors.
Company's competitiveness improved within Overall company, with revenue growth of 11.99 % and its market share increased to approx. 0 %. << More on XBIO Market Share.
*Market share is calculated based on total revenue.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Moonlake Immunotherapeutics's business model revolves around the development and commercialization of innovative immunotherapies for the treatment of diseases.
Biovie Inc is a biotechnology company that aims to develop advanced therapeutic solutions for various diseases. They have a unique business model that focuses on research and development of innovative drugs, strategic partnerships and collaborations with other organizations, along with potential commercialization of their products to generate revenue. Their goal is to create groundbreaking medical treatments that improve the quality of life for patients.
Vera Therapeutics Inc is a pharmaceutical company that specializes in developing and commercializing innovative therapies for patients with rare and serious diseases. Their business model focuses on researching and developing novel drug candidates, conducting clinical trials, and obtaining regulatory approvals to bring their products to market. By targeting niche patient populations with unmet medical needs, they aim to provide effective treatment options and improve patient outcomes.
Astria Therapeutics Inc's business model centers around developing and commercializing innovative therapeutics for various diseases and medical conditions.
Sources:
Xenetic Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Xenetic Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
